Phosphodiesterases as therapeutic targets for Huntington's disease
- PMID: 25159076
- DOI: 10.2174/1381612820666140826113957
Phosphodiesterases as therapeutic targets for Huntington's disease
Abstract
Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and emotional and psychiatric disturbances. The genetic mutation is characterized by a CAG expansion, resulting in the formation of a mutant huntingtin protein with an expanded polyglutamine repeat region. Mutated huntingtin has been shown to impair a number of physiological activities by interacting with several factors. In particular, cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) are severely affected by mutant huntingtin. In this view, drugs targeted at counteracting CREB loss of function and BDNF decrease have been considered as powerful tools to treat HD. Recently, cyclic nucleotide phosphodiesterase (PDE) inhibitors have been used successfully to increase levels of CREB and BDNF in HD models. Indeed, PDE4, 5 or 10 inhibitors have been shown to afford neuroprotection and modulation of CREB and BDNF. In this review, we will summarize the data supporting the use of PDE inhibitors as the therapeutical approach to fight HD and we will discuss the possible mechanisms of action underlying these effects.
Similar articles
-
Role of Phosphodiesterases in Huntington's Disease.Adv Neurobiol. 2017;17:285-304. doi: 10.1007/978-3-319-58811-7_11. Adv Neurobiol. 2017. PMID: 28956337 Review.
-
Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.CNS Neurosci Ther. 2018 Apr;24(4):319-328. doi: 10.1111/cns.12834. Epub 2018 Mar 3. CNS Neurosci Ther. 2018. PMID: 29500937 Free PMC article. Review.
-
Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.Neurobiol Dis. 2013 Apr;52:104-16. doi: 10.1016/j.nbd.2012.11.016. Epub 2012 Dec 7. Neurobiol Dis. 2013. PMID: 23220622
-
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.PLoS One. 2010 Oct 15;5(10):e13417. doi: 10.1371/journal.pone.0013417. PLoS One. 2010. PMID: 20976216 Free PMC article.
-
PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.Hippocampus. 2013 Aug;23(8):684-95. doi: 10.1002/hipo.22128. Epub 2013 Apr 29. Hippocampus. 2013. PMID: 23576401
Cited by
-
Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders.Inflammopharmacology. 2022 Dec;30(6):2051-2061. doi: 10.1007/s10787-022-01072-1. Epub 2022 Oct 22. Inflammopharmacology. 2022. PMID: 36272040 Review.
-
Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.Sci Rep. 2017 Sep 13;7(1):11469. doi: 10.1038/s41598-017-11664-5. Sci Rep. 2017. PMID: 28904388 Free PMC article.
-
Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.Neurotherapeutics. 2020 Jan;17(1):252-268. doi: 10.1007/s13311-019-00805-5. Neurotherapeutics. 2020. PMID: 31728850 Free PMC article.
-
Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications.Int J Neuropsychopharmacol. 2016 Apr 2;19(10):pyw030. doi: 10.1093/ijnp/pyw030. Int J Neuropsychopharmacol. 2016. PMID: 27037577 Free PMC article.
-
Selective Inhibition of PDE4B Reduces Binge Drinking in Two C57BL/6 Substrains.Int J Mol Sci. 2021 May 21;22(11):5443. doi: 10.3390/ijms22115443. Int J Mol Sci. 2021. PMID: 34064099 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical